Reuters logo
BRIEF-Eli Lilly updates on study data on Jardiance
June 13, 2017 / 6:15 PM / 3 months ago

BRIEF-Eli Lilly updates on study data on Jardiance

June 13 (Reuters) - Eli Lilly and Co:

* Jardiance® (empagliflozin) analysis reinforces established safety profile

* Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance versus placebo

* Adverse events were assessed in people who took at least one dose of Jardiance or placebo​

* An analysis of pooled safety data from 19 studies, including EMPA-REG OUTCOME trial, was well tolerated

* Ooverall safety profile of Jardiance in EMPA-REG OUTCOME was consistent with that of previous studies of Jardiance and current label information​

* Jardiance not associated with increased risk of hypoglycemia versus placebo, except in those who were on background sulfonylurea therapy​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below